“We believe this divestiture will allow our past innovations to reach more patients,” UCB stated, while reiterating its focus on advancing healthcare through partnerships.
Industry Impact and Antitrust Review
CBC Group’s CEO, Fu Wei, noted that acquiring UCB’s portfolio would bolster its central nervous system (CNS) biopharma platform in China, strengthening the firm’s healthcare ecosystem. “This acquisition serves as an anchor asset to further build out a leading integrated CNS biopharma platform,” he said.
The transaction, which is expected to close by December, is subject to antitrust clearances, though specific authorities were not mentioned.
UCB’s $680M Chinese Portfolio Sale : Advisors and Legal Counsel
Lazard is advising UCB on the financial aspects of the sale, while Freshfields Bruckhaus Deringer LLP is providing legal counsel. For CBC and Mubadala, PJT Partners Inc. is serving as financial adviser, and Clifford Chance LLP is acting as their legal adviser.
